AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Leerink Partners Reiterates Buy Rating on NovoCure Limited with $33 Price Target
ByAinvest
Thursday, Aug 14, 2025 8:32 pm ET1min read
Leerink Partners analyst Jonathan Chang has reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR), setting a price target of $33.00. The company reported solid Q2 2025 results, exceeding revenue expectations with $158.8 million, driven by a rise in active patient numbers. Chang also noted growth in prescriptions and active patients for Optune Lua in non-small cell lung cancer, suggesting potential for future growth.
Leerink Partners analyst Jonathan Chang has reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR), setting a price target of $33.00. The company reported solid Q2 2025 results, exceeding revenue expectations with $158.8 million, driven by a rise in active patient numbers. Chang also noted growth in prescriptions and active patients for Optune Lua in non-small cell lung cancer, suggesting potential for future growth.NovoCure Limited develops, manufactures, and commercializes Optune, a platform called Tumor Treating Field that employs electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company's strong Q2 performance was attributed to increased demand for its products, with a notable rise in active patient numbers across major markets.
Chang highlighted the company's ongoing efforts to expand its market reach and indicated that the potential for future growth in non-small cell lung cancer is promising. However, he also acknowledged that certain AI stocks may offer greater upside potential and carry less downside risk. For investors looking for undervalued AI stocks with significant upside potential, Chang suggested exploring other opportunities.
References:
[1] https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/is-novocures-nvcr-rising-active-patient-count-reshaping-its
[2] https://finance.yahoo.com/news/leerink-partners-reiterates-buy-rating-160832900.html
[3] https://ca.finance.yahoo.com/news/leerink-partners-reiterates-buy-rating-160832900.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet